GE Healthcare Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $5.1 billion, up 4% organically year-over-year, exceeding expectations.

Organic Orders Growth: 6% year-over-year, with a trailing 4-quarter average also at 6%.

Adjusted EBIT Margin: 14.8%, down 150 basis points year-over-year, impacted by tariffs.

Adjusted EPS: $1.07, down 6% year-over-year; excluding tariff impact, EPS would have increased in the high single digits.

Free Cash Flow: $483 million, with a 99% conversion rate, down $168 million year-over-year due to higher receivables and tariff payments.

2Strategic Updates and Business Highlights

Precision Care Strategy: Continued focus on executing this strategy, with strong demand for innovative solutions across all segments.

R&D Investments: Over $3 billion invested since 2022, leading to a new wave of product innovations.

Partnerships: A 14-year Care Alliance with UC San Diego Health to enhance cancer care through imaging solutions.

Acquisition: Planned acquisition of icometrix to enhance capabilities in Alzheimer's care.

Product Performance: Strong growth in contrast media and nuclear medicine, with a solid backlog of $21.2 billion.

3Forward Guidance and Outlook

2025 Guidance: Adjusted EPS raised to a range of $4.51 to $4.63 per share; organic revenue growth expected at approximately 3%.

Tariff Impact: Anticipated to affect adjusted EPS by approximately $0.45 for the year, with expectations for a lower net impact in 2026.

Free Cash Flow: Projected to be at least $1.4 billion for the full year.

4Bad News, Challenges, or Points of Concern

Margin Pressure: Adjusted EBIT margin decline attributed to tariffs and product holds, particularly in the Patient Care Solutions (PCS) segment, which saw a 7% revenue decline.

Product Hold: PCS faced challenges due to a product hold, significantly impacting revenue and margins; however, shipments have resumed.

Tariff Headwinds: Continued tariff impacts remain a concern, although mitigation strategies are in place.

5Notable Q&A Insights

China Market: Positive signs of recovery in China with improved tender activity; management remains optimistic about long-term growth potential despite past challenges.

Flyrcado Launch: Slower ramp-up expected in 2025, but confidence in achieving long-term revenue goals remains high; emphasis on ensuring a positive customer experience during the transition.

Electrophysiology Opportunities: Strong potential in the ASC market with new reimbursement structures supporting growth.

AI Integration: AI-enabled products are driving differentiation and growth, with expectations for significant contributions to revenue and margin expansion in the future. Overall, GE Healthcare reported solid Q3 results with a focus on innovation and strategic partnerships, while navigating challenges related to tariffs and product holds. The outlook remains positive with raised EPS guidance and a commitment to long-term growth strategies.